{"url_path":"/sec/lrmr/8-k/2026-05-14/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1374690/0001193125-26-222746-index.html","accession_number":"0001193125-26-222746","cik":"0001374690","ticker":"LRMR","issuer_name":"Larimar Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1374690/0001193125-26-222746-index.html","primary_entity_key":"0001374690","primary_entity_name":"Larimar Therapeutics, Inc."},"word_count":116,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\nBelow is a list of exhibits included with this Current Report on Form 8-K.\n\n \n\nExhibit No.\n\nDocument\n\n99.1\n\n \n\n[Press Release issued by Larimar Therapeutics, Inc. on May 14, 2026*](lrmr-ex99_1.htm)\n\n99.2\n\n \n\n[Larimar Therapeutics, Inc. Corporate Presentation, dated May 14, 2026](lrmr-ex99_2.htm)\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n* Furnished herewith\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nLarimar Therapeutics, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nMay 14, 2026\n\nBy:\n\n/s/ Carole S. Ben-Maimon, M.D.\n\n \n\n \n\n \n\nName: Carole S. Ben-Maimon, M.D.\nTitle: President and Chief Executive Officer"}